| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8eb7a434eb494c6306ec07c3b6a97776
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cf36c1f02e92a71be1b59dad016b577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2a310ed2fba068160512a6153457cc3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f4c2477bdea308bc9dec3feded37457 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2005-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35e446c0fd91c03319c397dec378261b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eaf044ba8d70834b74cb78ec6da5186 |
| publicationDate |
2005-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2005075681-A1 |
| titleOfInvention |
Method of examining sensitivity of cancer cell to anticancer agent |
| abstract |
In the case where the sensitivity of a cancer cell to a compound can be understood by examining molecules expressed in the cancer cell collected from a cancer patient by biopsy or the like, it is possible to administer the compound selectively to cancer patients on whom the compound can exert its antitumor effect. Thus, it is expected that the therapeutic effect can be enhanced while relieving unnecessary side effects thereby. More specifically speaking, it is found out that the characteristics “low pRB-expression”, “positive to p16 expression” and “high cyclin E-expression” are usable as a marker for the high sensitivity of cancer cells to this compound. Examination of these characteristics of cancer cells, therefore, the sensitivity of the cancer cells to this compound can be preliminarily understood. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008016187-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009092508-A |
| priorityDate |
2004-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |